535 related articles for article (PubMed ID: 12378382)
41. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
42. Effects of mild-to-moderate hyperglycaemia per se on glucose production and uptake in the elderly.
Paolisso G; Marrazzo G; de Riu S; Sgambato S; Varricchio M; d'Onofrio F; Lefèbvre P
Eur J Med; 1992 Apr; 1(1):6-12. PubMed ID: 1341981
[TBL] [Abstract][Full Text] [Related]
43. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
44. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
45. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.
D'Alessio DA; Kahn SE; Leusner CR; Ensinck JW
J Clin Invest; 1994 May; 93(5):2263-6. PubMed ID: 8182159
[TBL] [Abstract][Full Text] [Related]
46. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
Toft-Nielson M; Madsbad S; Holst JJ
Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
[TBL] [Abstract][Full Text] [Related]
47. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
Ritzel R; Orskov C; Holst JJ; Nauck MA
Diabetologia; 1995 Jun; 38(6):720-5. PubMed ID: 7672496
[TBL] [Abstract][Full Text] [Related]
49. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
50. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
51. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
Long SJ; Sutton JA; Amaee WB; Giouvanoudi A; Spyrou NM; Rogers PJ; Morgan LM
Br J Nutr; 1999 Apr; 81(4):273-9. PubMed ID: 10999014
[TBL] [Abstract][Full Text] [Related]
52. Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha.
Freeland KR; Wolever TM
Br J Nutr; 2010 Feb; 103(3):460-6. PubMed ID: 19818198
[TBL] [Abstract][Full Text] [Related]
53. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
55. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration.
Hargrove DM; Nardone NA; Persson LM; Parker JC; Stevenson RW
Metabolism; 1995 Sep; 44(9):1231-7. PubMed ID: 7666800
[TBL] [Abstract][Full Text] [Related]
56. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.
Dardevet D; Moore MC; Neal D; DiCostanzo CA; Snead W; Cherrington AD
Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E75-81. PubMed ID: 15026303
[TBL] [Abstract][Full Text] [Related]
57. Synergistic insulinotropic effects of succinic acid dimethyl ester and exendin-4 in anaesthetized rats.
Cancelas J; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
Int J Mol Med; 2001 Sep; 8(3):269-71. PubMed ID: 11494054
[TBL] [Abstract][Full Text] [Related]
58. Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.
Meneilly GS; McIntosh CH; Pederson RA; Habener JF; Gingerich R; Egan JM; Elahi D
J Gerontol A Biol Sci Med Sci; 2001 Nov; 56(11):M681-5. PubMed ID: 11682575
[TBL] [Abstract][Full Text] [Related]
59. Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin-4 injected animals.
Malendowicz LK; Nowak KW
Int J Mol Med; 2002 Sep; 10(3):327-31. PubMed ID: 12165809
[TBL] [Abstract][Full Text] [Related]
60. Type I diabetes mellitus does not alter initial splanchnic glucose extraction or hepatic UDP-glucose flux during enteral glucose administration.
Vella A; Shah P; Basu R; Basu A; Camilleri M; Schwenk WF; Rizza RA
Diabetologia; 2001 Jun; 44(6):729-37. PubMed ID: 11440366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
